In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in
patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4
timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images will
be analyzed to develop new biomarkers and to understand treatment effects.
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
1. Optimize Xe-MRI Oscillation Imaging for PAH. Regional mapping of oscillations in the
xenon RBC signal is a new technique that may provide new insights into microvascular
function in PH. Recent innovations in Xe-MRI have enabled improvements to this
methodology, but these have yet to be explored and optimized.
2. Quantify the short- and long-term repeatability of Xe-MRI oscillation imaging in
patients with PAH. Hyperpolarized 129Xe oscillation imaging is a novel technique that
may provide regional quantification of pulmonary microvascular function. However, the
repeatability of this technique has not been measured, which limits its use as an
3. Determine the minimum time-point at which Xe-MRI shows a clinically meaningful change
following treatment. Current standards in the PAH community are to assess treatment
efficacy in PAH patients at 3-6 months using 6MWTs, REVEAL Lite scores, echocardiograms,
and possibly RHCs. However, Xe-MRI may be more sensitive to functional improvements. We
hypothesize that Xe-MRI biomarkers will show a clinically meaningful change within 12
weeks of initiation of pulmonary vasodilators.
: Initiating Therapy
PAH patients who are newly initiating background therapy to treat pulmonary arterial hypertension.
PAH patients who are stable on therapy (On stable doses of background PAH therapy and diuretics for at least 90 days prior to screening).
Drug: - Hyperpolarized Xe129
Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
University of Kansas Medical Center
Kansas City, Kansas, 66160